Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis
Dementia affects more than 40 million people worldwide. When it is accompanied by psychosis, symptom management is especially challenging. Although no drug has been approved by the US Food and Drug Administration (FDA) for psychosis in patients with dementia, atypical antipsychotics are used off-lab...
Saved in:
Main Authors: | Ismaeel Yunusa (Author), Marie Line El Helou (Author), Saud Alsahali (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use
by: Ismaeel Yunusa, et al.
Published: (2020) -
Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics
by: Krithika Rajagopalan, et al.
Published: (2024) -
Falls and Fractures among Nursing Home Residents Treated with Pimavanserin versus Other Atypical Antipsychotics: Analysis of Medicare Beneficiaries with Parkinson's Disease Psychosis
by: Krithika Rajagopalan, et al.
Published: (2024) -
Novel Therapies to Address Unmet Needs in ITP
by: María Eva Mingot-Castellano, et al.
Published: (2022) -
Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admissions in Parkinson’s Disease Psychosis
by: Rajagopalan K, et al.
Published: (2024)